- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07920718
Development and Multicenter Validation of an Explainable System for Neonatal ARDS-Compatible Phenotyping
Development and Multicenter Validation of an Explainable System for Identifying Clinical Phenotypes Compatible With Neonatal Acute Respiratory Distress Syndrome
Neonatal acute respiratory distress syndrome (NARDS) can be difficult to identify consistently because relevant information is distributed across clinical notes, imaging reports, and respiratory support records. This study will develop and validate an explainable system that organizes routinely collected electronic health record information and identifies infants whose clinical findings are compatible with NARDS.
The study will involve three neonatal intensive care units in China. Historical records from the lead center will be used for system development. A later period at the lead center and independent records from the two collaborating centers will be used for temporal and geographic validation. After the system has been locked, newly eligible infants will be included in a prospective validation phase without changing their clinical care.
System results will be compared with an independent reference assessment by neonatal intensive care specialists. The specialists will classify each infant's first eligible respiratory event as a high-likelihood NARDS-compatible clinical phenotype, a non-compatible clinical phenotype, clinically uncertain, or insufficient information. The study will evaluate sensitivity, specificity, predictive values, review workload, and the ability to identify insufficient information. During prospective validation, system results will remain unavailable to treating clinicians. The system is being evaluated as a research screening and review tool; it is not intended to replace a full clinical diagnosis or to determine treatment.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Study design and objective This is a three-center observational cohort study combining retrospective system development and validation with prospective validation of a locked system. Its objective is to develop an explainable electronic health record-based system for identifying a NARDS-compatible clinical phenotype and prioritizing candidate records for specialist review.
Establishment of retrospective cohorts Historical NICU records dated January 1, 2018, through December 31, 2025, will provide the retrospective source population. Records from the lead center dated 2018-2022 will form the development cohort. Records from the lead center dated 2023-2025 will form an independent internal temporal validation cohort. Records from each collaborating center dated 2023-2025 will form two separate geographic external validation cohorts. The planned formal adjudication sample is approximately 1,600 candidate events for development and 800 candidate events in each of the three retrospective validation cohorts. Each infant's first eligible event will be used in the primary analysis.
Candidate screening and sampling Candidate records will be identified using prespecified evidence of respiratory support or escalation, bilateral or diffuse pulmonary imaging abnormalities, acute lung injury triggers, or relevant diagnostic expressions. Diagnostic codes will be used for screening and descriptive analyses.
System development and locking The system will extract traceable evidence from imaging reports and other permitted clinical records, including acute respiratory deterioration, acute lung injury triggers, pulmonary imaging abnormalities, and alternative explanations. It will assign high-priority review, routine review, or insufficient-information status and retain the supporting source and timestamp. The variable dictionary, text-processing rules, feature mappings, decision rules, thresholds, software version, and analysis plan will be locked before validation. No retraining, threshold selection, or center-specific tuning will use validation labels.
Reference standard Two qualified neonatal intensive care specialists will independently assess each evidence package using a prespecified adjudication manual. Disagreement will undergo independent arbitration and, when necessary, structured consensus. Adjudicators will be masked to system outputs, explanations, discharge diagnostic labels, and diagnostic codes. They will assign one of four categories: high-likelihood NARDS-compatible clinical phenotype, non-compatible clinical phenotype, clinically uncertain, or insufficient information. The high-likelihood phenotype requires an acute respiratory course, evidence of an acute lung injury trigger, bilateral or diffuse pulmonary parenchymal imaging abnormalities, and no single alternative explanation that fully accounts for the findings.
Prospective validation After retrospective temporal and geographic validation, the same locked system will be assessed in newly eligible infants at the participating centers. The proposed prospective phase will include consecutive eligible infants and will preserve the same index-event definition, evidence window, reference standard, and output categories. Results will be generated in silent mode and will not be displayed to treating clinicians or used to guide care. Independent adjudicators will remain masked to system outputs. Prospective sample size, center participation, recruitment dates, and consent arrangements will be finalized in the protocol and ethics documentation before this phase begins.
Performance analysis The primary measure will be sensitivity of high-priority review for the reference-standard high-likelihood phenotype in each independent validation cohort. Results will be presented separately for the lead-center temporal cohort, each external center, and the prospective phase, with center-specific prospective results when sample size permits. Ninety-five percent confidence intervals will accompany performance estimates. Sampling weights will be used when estimating performance in the historical candidate population. These categories will remain visible in study flow and sensitivity analyses. The primary analysis uses one event per infant.
Data governance Identifiable records, original free text, images, and identity linkage files will remain within each center's authorized environment. Locked code will preferentially be run locally at collaborating centers. Only approved aggregate results and the minimum permitted de-identified audit information will be transferred to the coordinating center. No research-specific treatment or additional biological sampling is planned.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Liyuan Hu, Ph.D.
- Telefoonnummer: +86-13816060888
- E-mail: nowadays921@126.com
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Infants in NICU at 3 participating hospitals before 44 weeks' postmenstrual age whose records meet ≥1 prespecified screening criterion for possible acute pulmonary injury. Historical candidates are sampled from prespecified center/calendar strata. The prospective phase consecutively enrolls newly eligible infants after system locking and retrospective validation. Separately identified screen-negative infants are reviewed if included in the registered screening audit. TTN, RDS, PPHN, pneumonia, and pulmonary hemorrhage are not automatic exclusions by diagnosis alone. Independent adjudication determines whether an alternative condition fully explains findings. Missing key evidence yields an uncertain/insufficient-information assessment, not automatic exclusion or a negative disease label.
Beschrijving
Inclusion Criteria:
- Receiving care in the NICU of a participating hospital before 44 weeks of postmenstrual age at the index event.
- Meeting at least one prespecified candidate screening criterion, including a relevant acute lung injury or NARDS/ARDS expression, respiratory support or support escalation, bilateral or diffuse pulmonary parenchymal abnormalities in an imaging report, or a prespecified acute lung injury trigger.
- Having records within the prespecified center and calendar-period cohort, or being newly eligible during the approved prospective validation period.
- Availability of an appropriate legal basis for use of the records, including parental or guardian consent or an ethics-approved waiver when applicable.
Exclusion Criteria:
- Structural lung or airway malformations, complex congenital heart disease, or clearly established cardiac dysfunction or fluid overload that fully explains the respiratory failure and imaging abnormalities.
- Short-term postoperative mechanical ventilation without evidence of acute pulmonary injury.
- Duplicate or unresolvable records that prevent reliable identification of the infant or index event.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: OTHER
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Sensitivity of high-priority review for the high-likelihood NARDS-compatible clinical phenotype
Tijdsspanne: One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after the first screening trigger (T0).
|
We will calculate the high-priority proportion among expert-adjudicated NARDS-compatible infants, excluding routine-review and insufficient-information outputs, and report performance with 95% CIs by cohort, with uncertain assessments reported separately. |
One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after the first screening trigger (T0).
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Positive predictive value of high-priority review
Tijdsspanne: One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after T0.
|
Among high-priority infants with determinate reference, report adjudicated high-likelihood NARDS-compatible proportion and 95% CI by cohort. Enriched samples yield sampling-weighted candidate estimates if permitted. It is not NICU-wide incidence. |
One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after T0.
|
|
Negative predictive value for the high-priority triage policy
Tijdsspanne: One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after T0.
|
Among determinate-reference non-high-priority infants, report non-compatible phenotype proportion and 95%CI by cohort; describe routine-review and insufficient-information outputs separately, to avoid concealment. Weight historical estimates if possible. |
One assessment per first eligible respiratory event, using records from 48 hours before to 48 hours after T0.
|
|
Proportion of infants with a determinate reference-standard assessment
Tijdsspanne: At reference adjudication of the first eligible event, using the same records from 48 hours before to 48 hours after T0.
|
Assessed infants with high-likelihood NARDS-compatible or non-compatible phenotype divided by all assessed; uncertain and insufficient-information assessments reported separately with reasons and 95% CIs, not relabeled negative or removed from flow. |
At reference adjudication of the first eligible event, using the same records from 48 hours before to 48 hours after T0.
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Studie stoel: Liyuan Hu, Ph.D., Guangzhou Women and Children's Medical Center
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2026-419A01
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .